Get the Stockscreener App
0.323
3.29%
-0.011
After Hours:
.33
0.007
+2.17%
Werewolf Therapeutics Inc stock is traded at $0.323, with a volume of 688.65K.
It is down -3.29% in the last 24 hours and down -30.25% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
See More
Previous Close:
$0.334
Open:
$0.33
24h Volume:
688.65K
Relative Volume:
1.30
Market Cap:
$15.70M
Revenue:
$1.14M
Net Income/Loss:
$-56.27M
P/E Ratio:
-0.2661
EPS:
-1.2139
Net Cash Flow:
$-51.94M
1W Performance:
-8.06%
1M Performance:
-30.25%
6M Performance:
-50.63%
1Y Performance:
-71.67%
1-Day Range:
$0.3133
$0.3624
1-Week Range:
$0.3133
$0.3811
52-Week Range:
$0.3133
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.323 | 16.23M | 1.14M | -56.27M | -51.94M | -1.2139 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Form 13D/A WEREWOLF THERAPEUTICS For: 26 June By Investing.com - Investing.com Canada
RA Capital reports 6% Werewolf Therapeutics (HOWL) stake after June share sales - Stock Titan
Werewolf Therapeutics details cancer pipeline progress, shares watched by biotech investors - Ad-hoc-news.de
Werewolf Therapeutics, Inc. Actuals & Estimates (NASDAQ:HOWL) - TradingView
Werewolf Therapeutics Inc (HOWL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Werewolf Therapeutics Inc (HOWL) Institutional Confidence - TradingKey
Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock By Investing.com - Investing.com Australia
Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock - Investing.com UK
[SCHEDULE 13D/A] Werewolf Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Form 4 Werewolf Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
RA Capital funds trim Werewolf Therapeutics (HOWL) stake with 416,911-share sale - Stock Titan
RA Capital Management Reduces Stake in Werewolf Therapeutics Inc - GuruFocus
Werewolf Therapeutics Inc (HOWL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Werewolf Therapeutics Inc (HOWL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Werewolf Therapeutics Inc (HOWL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Werewolf Therapeutics Inc (HOWL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Werewolf Therapeutics Inc (HOWL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Werewolf Therapeutics Inc (HOWL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Werewolf Therapeutics Inc (HOWL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ra Capital Management reduces Werewolf Therapeutics stake by $173,757 - Investing.com UK
RA Capital trims Werewolf Therapeutics (HOWL) stake with 448,836-share sale - Stock Titan
RA Capital adjusts Werewolf Therapeutics (HOWL) stake to 10.6% ownership - Stock Titan
Werewolf Therapeutics Stock (US4433141076): valuation back in focus after recent pipeline updates - Ad-hoc-news.de
Werewolf Therapeutics Stock (US4433141076): Quarterly earnings keep biotech micro-cap in focus - Ad-hoc-news.de
Ra Capital sells $253,568 in Werewolf Therapeutics (NASDAQ:HOWL) stock By Investing.com - Investing.com Canada
Ra Capital sells $253,568 in Werewolf Therapeutics (NASDAQ:HOWL) stock - Investing.com
RA Capital funds trim Werewolf Therapeutics (HOWL) stake with 678K-share sale - Stock Titan
Werewolf Therapeutics director Evnin sells $28,463 in company stock - Investing.com UK
Werewolf Therapeutics (HOWL) entities linked to Luke Evnin sell 76,928 shares - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Werewolf Therapeutics director Luke Evnin sells $43,028 in shares - Investing.com UK
Werewolf Therapeutics director Luke Evnin sells $43,028 in shares By Investing.com - Investing.com India
Werewolf Therapeutics (NASDAQ: HOWL) director’s entities sell shares - Stock Titan
Werewolf Therapeutics director Luke Evnin sells $63,628 in stock By Investing.com - Investing.com India
Werewolf Therapeutics director Luke Evnin sells $63,628 in stock - Investing.com
Werewolf Therapeutics (NASDAQ: HOWL) director-affiliated funds sell 139,803 shares - Stock Titan
Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update - Bez Kabli
Werewolf Therapeutics (HOWL) Slips to $0.45 as Biotech Stock Holds Near Critical SupportDark Pool Volume - newsline.com
Werewolf Therapeutics Inc. Q1 2026 Earnings: Narrower Loss Surprises as Pipeline Progress ContinuesCEO Earnings Statement - The Legal Advocate
What's Behind the Recent Insider Selling at Werewolf Therapeutics (HOWL) - Kavout
Werewolf Therapeutics director Luke Evnin sells $66,200 in shares By Investing.com - Investing.com India
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):